5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer.
OBJECTIVE
To evaluate the regimen of 5-fluorouracil (5-FU) and mitomycin-C (MMC) in terms ofresponse rate and overall survival in advanced colorectal cancer.


METHODS
Between January 1993 and December 2000, 121 from 559 patients with advanced colorectal cancer were treated with chemotherapy. Bolus MMC (10 mg/m2) on first day, 5-FU (600 mg/m2/day) was given as a continuous infusion for 5 days, repeated every 4 weeks for 6 cycles. Toxicity and response were analyzed according to WHO criteria, and survival was analyzed according to Kaplan-Meier methodology.


RESULTS
In the chemotherapy group (121 patients), 70 were males and 51 were females, the mean age was 52 years. The ratio of colon and rectal cancer was 0.57. Nearly all patients (88.89%) had tumors with moderate differentiation. Forty patients with liver metastasis showed an overall response rate of 45% (95% CI 35.4-54.6) with a CR in 3 (7.5%) and PR in 15 (37.5%). The median survival was 13.1 months. The regimen was well tolerated with 11.64% of patients experiencing WHO grade 3-4 toxicity.


CONCLUSIONS
The present study has indicated a highly active, acceptable toxic, inexpensive regimen of old drugs to be used as an alternative to the more expensive combination including CPT-11 or oxaliplatin.
Aphinives
Potchavit
P
Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand. potchavit@yahoo.com
Bhudhisawasdi
Vajarabhongsa
V
Sae-seow
Otur
O
Uttaravichien
Thongueb
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000191:economics; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000401:mortality; D004334:Drug Administration Schedule; D016527:Drug Costs; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D009944:Organoplatinum Compounds / Q000191:economics; D000077150:Oxaliplatin; D012189:Retrospective Studies; D015996:Survival Rate
D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D016685:Mitomycin; D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin